New evidence underscores TumorSight® Viz’s ability to deliver reproducible landmark identification and measurement for early-stage breast cancer surgical planning CHICAGO, IL – March 5, 2026 – SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, today…
Company strengthens AI and technology leadership as it advances next-generation precision oncology platform CHICAGO, IL – January 27, 2026 – SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, today announced the appointment of Senthil Periaswamy,…
Vincent Reid, MD, FACS, Chairman of Surgery and Medical Director at the Hall Perrine Cancer Center, Mercy Cedar Rapids, to share clinical experience and real-world case studies using TumorSight™ Viz CHICAGO, IL and EXTON, PA – December 2, 2025 –…
National feature spotlights TumorSight™ Viz’s clinical use at Mercy Cedar Rapids and initiative with NVIDIA advancing AI-powered precision breast cancer care CHICAGO, IL – October 27, 2025 – SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and…
Commercial partnership expected to accelerate adoption of SimBioSys’ AI-powered surgical visualization platform following recent FDA clearance of TumorSight Viz 1.3 CHICAGO, IL and EXTON, PA, August 27, 2025 – SimBioSys®, a clinical AI company leveraging spatial biophysics to drive precision…
Latest release introduces industry-leading AI performance, optimized workflow integration, and enhanced surgeon usability to streamline imaging-to-intervention planning CHICAGO, July 9, 2025 /PRNewswire/ — SimBioSys®, a clinical AI company leveraging spatial biophysics to drive precision in breast cancer treatment, today announced its third…
Company to share fresh vision and transformative plans for its next chapter at the J.P. Morgan Healthcare Conference CHICAGO, IL – January 9, 2025 – SimBioSys, a pioneering TechBio company revolutionizing cancer care with advanced AI and spatial biophysics, today…
Our presence at ASBrS will be an excellent opportunity to demonstrate how this synergy has the potential to benefit surgeons and patients by providing a clearer understanding of complex cancer surgeries before the first incision is made. EXTON, Pa. &…
PhenoScope™, SimBioSys’ powerful proprietary technology and service, can analyze vast fields of multi-modal data seamlessly, generating novel insights, including unique spatial biophysical insights in a 4-dimension space, for cancer drug discovery and development which are not apparent by looking at…
CHICAGO–(BUSINESS WIRE)–SimBioSys®, a trailblazing TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine cancer precision medicine, transform patient care and defeat cancer today announced the strategic appointment of Jyoti Palaniappan as Chief Commercial Officer…
SOLUTIONS
- TumorSight Viz
- TumorSight RISK
- PhenoScope
RESOURCES
©SimBioSys